Premier Vein & Vascular Center: Houston's Leading Destination for Expert Vein & Fibroid Treatments
Premier Vein & Vascular Center, a trusted leader in vascular and fibroid treatments, is setting new standards for specialized care in Houston. With board-certified specialists and state-of-the-art, minimally invasive procedures, the clinic is dedicated to helping patients achieve relief from painful, unsightly vein conditions and fibroid-related discomfort.
Houston, TX - Premier Vein & Vascular Center, a leading vein clinic in Houston, is proud to offer a comprehensive range of cutting-edge, minimally invasive treatments for a variety of vein and vascular conditions. With over 20 years of experience, our board-certified vein doctors are dedicated to providing patient-centered care that focuses on both cosmetic improvements and long-term vascular health.
At Premier Vein & Vascular Center, patients have access to advanced treatments for varicose veins, using safe, gentle procedures to eliminate painful, bulging veins and restore confidence. Our vein clinic also specializes in spider vein treatment through highly effective sclerotherapy injections that leave the skin smooth and clear. Chronic pelvic pain caused by pelvic congestion syndrome is treated with advanced embolization techniques for lasting relief. For patients suffering from chronic knee pain, Genicular Artery Embolization (GAE) offers a minimally invasive option to help restore mobility. Women experiencing discomfort from uterine fibroids can benefit from Uterine Fibroid Embolization (UFE), a non-surgical procedure designed to reduce fibroids while preserving the uterus. In addition, our vein doctors offer expert care for venous ulcers with advanced healing therapies and compression treatments. Patients with Peripheral Arterial Disease (PAD) are treated using innovative procedures that restore healthy blood flow and improve function. For those diagnosed with Deep Vein Thrombosis (DVT), our clinic provides state-of-the-art care to dissolve dangerous blood clots and protect overall vascular health.
'Vein disorders are not just cosmetic—they can deeply affect a person's mobility and quality of life,' said Dr. Raza, one of Houston's leading vein doctors at Premier Vein & Vascular Center. 'At our vein clinic, we are committed to delivering advanced, minimally invasive solutions that help our patients return to pain-free, active living.'
Premier Vein & Vascular Center is proud to be an IAC-accredited vein clinic, recognized for meeting the highest standards of quality in vascular care. With two convenient Houston locations, patients benefit from same-week consultations and a smooth, expert-guided treatment process tailored to their needs.
Patients consistently rate Premier Vein & Vascular Center as Houston's top-rated vein clinic. Johanna Alejandre shared, 'Best staff ever! After 20 years, I can finally wear shorts again thanks to their varicose vein treatments.' Kayla LeMoine said, 'Dr. Raza and his team made me feel completely at ease. My procedure took only 10 minutes!' Rebecca Blake added, 'Highly professional and efficient. I recommend this clinic 110%!'
Premier Vein & Vascular Center is currently offering complimentary vein consultations for new patients. To schedule an appointment with an experienced vein doctor, call (832) 974-2329 or visit us at 19255 Park Row, Suite 201, Houston, TX 77084.
Media Contact
Email: Send Email
Phone: (832) 321-5355
Address:19255 Park Row Dr Suite 201
City: Houston
State: TX
Country: United States
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
09-07-2025
- Associated Press
South Florida Vascular Associates Introduces Genicular Artery Embolization (GAE) for Knee Osteoarthritis Relief
Summary: South Florida Vascular Associates introduces Genicular Artery Embolization (GAE) as a treatment option for knee osteoarthritis, offering a faster recovery, reduced pain, and an alternative to surgery. Coconut Creek, Florida--(Newsfile Corp. - July 9, 2025) - South Florida Vascular Associates recently announced the launch of Genicular Artery Embolization (GAE), a minimally invasive procedure designed to alleviate pain associated with knee osteoarthritis (OA). This innovative treatment provides patients with alternative means of managing chronic knee pain before considering invasive options, such as surgery. The launch of GAE aligns with South Florida Vascular Associates' commitment to offering advanced, image-guided procedures that address the growing need for non-invasive treatments. GAE allows for a quicker recovery time, with most procedures taking only 60 to 90 minutes, enabling patients to return home the same day. This aligns with the growing demand for outpatient treatments, which offer patients a convenient and cost-effective option for relief without the downtime typically associated with surgery. Osteoarthritis (OA) of the knee is a widespread condition that has been on the rise for decades. While it is often associated with an aging population, changes in lifestyle and activity factors have also led to younger adults developing OA. By introducing GAE, South Florida Vascular Associates aims to help more people and ensure they lead more fulfilling lives. As part of its approach to offering this new procedure, South Florida Vascular Associates has ensured that all staff members are fully trained in the latest techniques for GAE, enabling a seamless process for patients from initial consultation to post-procedure recovery. The clinic has also integrated the procedure into its existing workflow to ensure consistent, high-quality care across all stages of treatment. South Florida Vascular Associates has reiterated its commitment to continually improving its services by evaluating new image-guided techniques. In addition to staying current with medical advancements, the practice is committed to integrating techniques that align with its goals of safety, outpatient care, and oversight. The practice believes that this will help patients avoid invasive procedures and, more importantly, unnecessary hospital visits. Additionally, South Florida Vascular Associates, through its founder, Dr. William Julien, emphasizes the importance of ongoing procedural development, particularly in the field of interventional medicine. The technology is continually improving, and the vascular interventional physician believes this is good news for patients. While this involves adding services for business and is often part of their internal growth, the clinic points out that the primary goal should be improving patient care. As knee osteoarthritis continues to affect millions of people, the introduction of GAE by South Florida Vascular Associates represents a significant step forward in providing patients with a more accessible and less invasive treatment option. With GAE, patients now have a viable alternative to traditional surgery, offering them hope for a more comfortable, pain-free future. About South Florida Vascular Associates: South Florida Vascular Associates has been serving patients in need of vascular care for more than 20 years. The clinic offers minimally invasive treatments, including uterine, prostate, and varicocele embolization, and is committed to patient safety, leveraging technology to provide advanced and efficient treatments. Media Contact: [ This image cannot be displayed. Please visit the source: ] To view an enhanced version of this graphic, please visit: Company Name: South Florida Vascular Associates Contact Person: Roco Julien Phone: (954) 725-4141 Address: 5300 W Hillsboro Blvd, Suite 107 City: Coconut Creek State: Florida Postal Code: Country: United States Website: To view the source version of this press release, please visit
Yahoo
25-06-2025
- Yahoo
UFE Doesn't Remove Fibroids--Here's What Women Aren't Being Told
WASHINGTON, June 25, 2025 /PRNewswire/ -- Every year, thousands of women are steered toward a fibroid treatment that doesn't actually remove fibroids. Uterine Fibroid Embolization (UFE) may sound minimally invasive but it doesn't remove fibroids; it just shrinks them, slightly, often with disappointing results. At the Center for Innovative GYN Care (CIGC), we believe women deserve the truth—and real options—before making a decision that impacts their fertility, health, and future. "UFE may shrink fibroids slightly, but it rarely makes a meaningful difference—especially with large or complex cases," said Dr. Natalya Danilyants, board-certified GYN surgeon and co-founder of CIGC. "The fibroids are still inside your body, and so are the symptoms. For many women, the pain, pressure, and bleeding continue—or even worsen—because the root problem was never removed," she added. Fibroids are very common and affect approximately 80% of women…By age 50, about 80% of women will have fibroids." THE HIDDEN COSTS OF UFE Too many women are told UFE is their best option. But here's what they're not being told: Fibroids will remain in the body after UFE—and can grow back. Fertility can be reduced due to impaired blood flow to the uterus or ovaries. Large or complex fibroids? UFE often fails to relieve symptoms or prevent repeat procedures. Coexisting conditions like endometriosis or adenomyosis go undiagnosed—because UFE can't detect or treat them. UFE may delay the treatment you actually need. PROVEN ALTERNATIVE: COMPLETE REMOVAL, FASTER RECOVERY For more than 18 years, CIGC has been providing minimally invasive outpatient procedures that fully remove fibroids—even large, complex, or multiple growths—through just two tiny incisions: LAAM® Myomectomy: A fertility-sparing surgery that could improve your chances of getting pregnant. DualPortGYN®: Our advanced laparoscopic technique for hysterectomy or fibroid removal. 7–10 day recovery at home—not weeks in pain. Both options are performed in our surgical centers by board-certified GYN surgeons—and patients are able to go home the same day and be back to work in under two weeks. ONE SURGERY. REAL ANSWERS. Unlike UFE, our surgeons can also diagnose and remove endometriosis, cysts, or adenomyosis—and send all tissue to pathology for testing. That means you leave surgery knowing what was inside your body… and what wasn't. If you've been told your fibroids are "not that bad" or pushed toward a one-size-fits-all procedure like UFE, it's time to rethink your care. Book a consultation with a gynecologic surgeon to get answers—and take control of your health. "We believe women deserve much more than symptom management. They deserve validation, compassion, and swift resolution," said Dr. Danilyants. About the Center for Innovative GYN Care CIGC is a national leader in minimally invasive GYN surgery, with advanced surgical centers serving women across the DC, Maryland, Virginia (DMV) region and New Jersey. Our reputation for excellence draws patients from across the U.S. and around the world—thanks to our groundbreaking outpatient procedures, short recovery times, and life-changing results. Our board-certified, fellowship-trained surgeons specialize in the complete removal of complex fibroids, endometriosis, and chronic pelvic pain—with a singular focus on compassionate, patient-first care. Visit our website or follow us on Instagram or YouTube to learn more. Press Contact: Jasmin Ramsey PR & Marketing Managersocial@ View original content to download multimedia: SOURCE The Center for GYN Care
Medscape
24-06-2025
- Medscape
Semaglutide Shows Benefits for PAD Across T2D Subgroups
CHICAGO — Use of the GLP-1 receptor agonist semaglutide improved walking capability in patients with peripheral arterial disease (PAD) and type 2 diabetes (T2D), regardless of duration of diabetes, BMI, or glycemic control, a post-hoc analysis of phase 3 double-blind randomized STRIDE showed. 'PAD remains a recalcitrant problem in people living with diabetes. We need solutions for improving quality of life and preventing limb loss' said senior study author Subodh Verma, MD, PhD, a cardiovascular surgeon and professor of medicine at the University of Toronto, Canada, here at the American Diabetes Association (ADA) 85th Scientific Sessions, where the results were presented. The data was simultaneously published online in Diabetes Care . About 230 million people globally — and up to a third of those with diabetes — have PAD, which is why the ADA recommends using ankle-brachial index testing in individuals with T2D who are over 65 and meet certain criteria. The STRIDE Study STRIDE was conducted at 112 sites in 20 countries, enrolling 792 patients aged 18 years and older with T2D and PAD with intermittent claudication and reduced ankle-brachial or toe-brachial index. The median age was 68 years, the mean diabetes duration was 13.3 years, and 195 (25%) participants were female and 597 (75%) were male. Patients were randomized to subcutaneous semaglutide 1 mg per week for 52 weeks (n = 396) or to placebo (n = 396). The primary analysis of the trial, presented at the American College of Cardiology Scientific Session 2025 in March, showed that semaglutide significantly improved walking distance, pain, and quality of life in patients with symptomatic PAD and T2D. It was also associated with reductions in disease progression and use of rescue therapy and improvement in ankle-brachial index. At baseline, trial participants could walk a maximum of 184 m, and the pain-free walking distance was 119 m. Two-thirds of the individuals said PAD moderately-to-severely impacted quality of life. At week 52, patients taking once-weekly semaglutide had a roughly 40-m improvement in maximum walking distance, and a 30-m improvement in pain-free walking distance on a treadmill with a fixed speed of 3.2 kph (2.3 mph) and fixed inclination of 12%, when compared with placebo. For the current analysis, the researchers stratified the participants by baseline T2D characteristics. The mean BMI was 29.6; 41% had a BMI > 30, and 44% had A1C < 7%. Only a third used insulin and a third used an SGLT2 inhibitor. Their analysis showed no meaningful distinction between the subgroups for improvement in either maximum walking distance or pain-free walking distance, said lead author Neda Rasouli, MD, professor of medicine at the University of Colorado Anschutz Medical Campus, Aurora, at the meeting. The estimated treatment ratio favored semaglutide regardless of diabetes duration, BMI, A1C, or medication used, she added. These findings support semaglutide's 'consistent efficacy and safety profile across the spectrum of type 2 diabetes, including those who are non-obese and have well-controlled diabetes,' she concluded. Vascular Medications 'This was a really important study,' said Kim Eagle, MD, the Albion Walter Hewlett professor of internal medicine at the University of Michigan, when asked to comment by Medscape Medical News . Eagle said that while the additional 40 m of walking distance might not seem huge, it could be meaningful for a golfer, for instance, who could walk that much further to their ball, without a golf cart. 'We're still learning about the effects of GLP-1s,' said Eagle, who is also director of the Frankel Cardiovascular Center at the University of Michigan. 'They clearly affect vascular function,' he said, adding that the effects in PAD would be expected for the entire class. 'The thesis here is that these are vascular medications,' said Verma, noting in a briefing with reporters that patients had an improvement in hemodynamics. The improvement is not driven by changes in weight or A1C, he added. Given the results of STRIDE and the post-hoc analysis, 'I would suggest that it should be strongly considered by our patients living with PAD and diabetes as a strategy to not only improve MACE outcomes, but to also improve functional outcomes in PAD,' said Verma. Eagle noted, however, that clinicians often face barriers in prescribing GLP-1s. 'We're basically scrambling to see what's covered by patients' insurance,' he said. Verma and his co-authors said that more research is needed to understand if semaglutide's benefits extend to people with PAD who do not have diabetes. The study was funded by Novo Nordisk A/S. Rasouli reported receiving consultation fees and/or research funding from Novo Nordisk, Eli Lilly, Sanofi and SomaLogic. Verma disclosed research grants and/or speaking fees from Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, HLS Therapeutics, Anthos, Janssen, Novartis, Novo Nordisk, Pfizer, PhaseBio, S&L Solutions Event Management, and Sanofi. Eagle reported no relevant conflicts.
